Nanoparticles and microparticles as vaccine-delivery systems

References

• Ramon G. Sur la toxine st sur l’anatoxine diptheriques. Ann. Inst. Pasteur38, 1–10 (1924).
   Google Scholar
• Vogel FR, Pruett MF. A compendium of vaccine adjuvants and excipients. In: Vaccine Design. The Subunit and Adjuvant Approach. Newman MJ (Ed.). Plenum Press, NY, USA 141–228 (1995).
   Google Scholar
• Mesa C, Fernandez LE. Challenges facing adjuvants for cancer immunotherapy. Immunol. Cell. Biol.82(6), 644–650 (2004).
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Fragapane E, Bugarini R et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin. Vaccine Immunol.13(9), 1010–1013 (2006).
   PubMed Web of Science ®Google Scholar
• Gupta RK. Aluminum compounds as vaccine adjuvants. Adv. Drug Del. Rev.32, 155–172 (1998).
   PubMed Web of Science ®Google Scholar
• Lindblad EB. Aluminium compounds for use in vaccines. Immunol. Cell. Biol.82(5), 497–505 (2004).
   PubMed Web of Science ®Google Scholar
• Singh M, Ugozzoli M, Kazzaz J et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine24(10), 1680–1686 (2006).
   PubMed Web of Science ®Google Scholar
• Relyveld EH, Bizzini B, Gupta RK. Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine16(9–10), 1016–1023 (1998).
   PubMed Web of Science ®Google Scholar
• Edelman R. Adjuvants for the future. New Generation Vaccines. Cobson GS (Ed.). Marcel Dekker Inc., NY, USA 173–192 (1997).
   Google Scholar
• Zinkernagel RM, Ehl S, Aichele P et al. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol. Rev.156, 199–209 (1997).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev. Vaccines2(2), 269–283 (2003).
   PubMedGoogle Scholar
• Fearon DT. Seeking wisdom in innate immunity. Nature388(6640), 323–324 (1997).
   PubMed Web of Science ®Google Scholar
• Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science272(5258), 50–53 (1996).
   PubMed Web of Science ®Google Scholar
• Yip HC, Karulin AY, Tary-Lehmann M et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J. Immunol.162(7), 3942–3949 (1999).
   PubMed Web of Science ®Google Scholar
• Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug Deliv. Rev.57(3), 391–410 (2005).
   PubMed Web of Science ®Google Scholar
• Cui Z, Mumper RJ. Microparticles and nanoparticles as delivery systems for DNA vaccines. Crit. Rev. Ther. Drug Carrier Syst.20(2–3), 103–137 (2003).
   PubMed Web of Science ®Google Scholar
• Wendorf J, Singh M, Chesko J et al. A practical approach to the use of nanoparticles for vaccine delivery. J. Pharm. Sci.95(12), 2738–2750 (2006).
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev.55(3), 329–347 (2003).
   PubMed Web of Science ®Google Scholar
• Kreuter J. Nanoparticles as adjuvants for vaccines. Pharm. Biotechnol.6, 463–472 (1995).
   PubMedGoogle Scholar
• Jung T, Kamm W, Breitenbach A et al. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm. Res.18(3), 352–360 (2001).
   PubMed Web of Science ®Google Scholar
• Singh M, Briones M, Ott G, O’Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl Acad. Sci. USA97(2), 811–816 (2000).
   PubMed Web of Science ®Google Scholar
• Diwan M, Tafaghodi M, Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J. Control Release85(1–3), 247–262 (2002).
   PubMed Web of Science ®Google Scholar
• Kreuter J, Speiser PP. New adjuvants on a polymethylmethacrylate base. Infect. Immun.13(1), 204–210 (1976).
   PubMed Web of Science ®Google Scholar
• Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun.59(9), 2978–2986 (1991).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Jeffery H, Davis SS. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine11(9), 965–969 (1993).
   PubMed Web of Science ®Google Scholar
• Nakaoka R, Inoue Y, Tabata Y, Ikada Y. Size effect on the antibody production induced by biodegradable microspheres containing antigen. Vaccine14(13), 1251–1256 (1996).
   PubMed Web of Science ®Google Scholar
• Tabata Y, Inoue Y, Ikada Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine14(17–18), 1677–1685 (1996).
   PubMed Web of Science ®Google Scholar
• Gutierro I, Hernandez RM, Igartua M, Gascon AR, Pedraz JL. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine21(1–2), 67–77 (2002).
   PubMed Web of Science ®Google Scholar
• Vila A, Sanchez A, Evora C et al. PEG-PLA nanoparticles as carriers for nasal vaccine delivery. J. Aerosol Med.17(2), 174–185 (2004).
   PubMedGoogle Scholar
• Kohane DS. Microparticles and nanoparticles for drug delivery. Biotechnol. Bioeng.96(2), 203–209 (2007).
   PubMed Web of Science ®Google Scholar
• Peltonen L, Koistinen P, Karjalainen M, Hakkinen A, Hirvonen J. The effect of cosolvents on the formulation of nanoparticles from low-molecular-weight poly(L)lactide. AAPS Pharm. Sci. Tech.3(4), E32 (2002).
   PubMedGoogle Scholar
• Wehrle P, Magenheim B, Benita S. The influence of process parameters on the PLA nanoparticle size distribution, evaluated by means of factorial design. Eur. J. Pharm. Biopharm.41(1), 19–26 (1995).
   Web of Science ®Google Scholar
• Scholes PD, Coombes AGA, Illum L et al. The preparation of sub-200 nm poly(lactide-co-glycolide) microspheres for site-specific drug delivery. J. Control Release25(1–2), 145–153 (1993).
   Web of Science ®Google Scholar
• Blanco MD, Alonso MJ. Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres. Eur. J. Pharm. Biopharm.43(3), 287–294 (1997).
   Web of Science ®Google Scholar
• Nguyen XC, Herberger JD, Burke PA. Protein powders for encapsulation: a comparison of spray-freeze drying and spray drying of darbepoetin alfa. Pharm. Res.21(3), 507–514 (2004).
   PubMed Web of Science ®Google Scholar
• Thomasin C, Merkle HP, Gander B. Drug microencapsulation by PLA/PLGA coacervation in the light of thermodynamics. 2. Parameters determining microsphere formation. J. Pharm. Sci.87(3), 269–275 (1998).
   PubMed Web of Science ®Google Scholar
• Thomasin C, Ho NT, Merkle HP, Gander B. Drug microencapsulation by PLA/PLGA coacervation in the light of thermodynamics. 1. Overview and theoretical considerations. J. Pharm. Sci.87(3), 259–268 (1998).
   PubMed Web of Science ®Google Scholar
• Tamber H, Johansen P, Merkle HP, Gander B. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv. Drug Deliv. Rev.57(3), 357–376 (2005).
   PubMed Web of Science ®Google Scholar
• Cleland JL, Jones AJ. Stable formulations of recombinant human growth hormone and interferon-γ for microencapsulation in biodegradable microspheres. Pharm. Res.13(10), 1464–1475 (1996).
   PubMed Web of Science ®Google Scholar
• Kazzaz J, Neidleman J, Singh M, Ott G, O’Hagan DT. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J. Control. Release67(2–3), 347–356 (2000).
   PubMed Web of Science ®Google Scholar
• Singh M, Kazzaz J, Chesko J et al. Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J. Pharm. Sci.93(2), 273–282 (2004).
   PubMed Web of Science ®Google Scholar
• Singh M, Kazzaz J, Ugozzoli M et al. Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr. Drug Deliv.3, 115–120 (2006).
   PubMedGoogle Scholar
• Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm.55(1), R1–R4 (1989).
   Web of Science ®Google Scholar
• Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with DL-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J. Control. Release25(1–2), 89–98 (1993).
   Web of Science ®Google Scholar
• Molpeceres J, Guzman M, Aberturas MR, Chacon M, Berges L. Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement. J. Pharm. Sci.85(2), 206–213 (1996).
   PubMed Web of Science ®Google Scholar
• Calvo P, RemunanLopez C, VilaJato JL, Alonso MJ. Development of positively charged colloidal drug carriers: chitosan coated polyester nanocapsules and submicron-emulsions. Coll. Polym. Sci.275(1), 46–53 (1997).
   Web of Science ®Google Scholar
• Jung T, Breitenbach A, Kissel T. Sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide)s facilitate the preparation of small negatively charged biodegradable nanospheres. J. Control. Release67(2–3), 157–169 (2000).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Palin KJ, Davis SS. Poly(butyl-2-cyanoacrylate) particles as adjuvants for oral immunization. Vaccine7(3), 213–216 (1989).
   PubMed Web of Science ®Google Scholar
• Chauvierre C, Labarre D, Couvreur P, Vauthier C. Novel polysaccharide-decorated poly(isobutyl cyanoacrylate) nanoparticles. Pharm. Res.20(11), 1786–1793 (2003).
   PubMed Web of Science ®Google Scholar
• Major M, Prieur E, Tocanne JF, Betbeder D, Sautereau AM. Characterization and phase behaviour of phospholipid bilayers adsorbed on spherical polysaccharidic nanoparticles. Biochim. Biophys. Acta1327(1), 32–40 (1997).
   PubMed Web of Science ®Google Scholar
• Baudner BC, Balland O, Giuliani MM et al. Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. Infect. Immun.70(9), 4785–4790 (2002).
   PubMed Web of Science ®Google Scholar
• Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit. Rev. Ther. Drug Carrier Syst.12(1), 1–99 (1995).
   PubMed Web of Science ®Google Scholar
• Putney SD, Burke PA. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol.16(2), 153–157 (1998) [erratum: Nat. Biotechnol.16(5), 478 (1998)].
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Jeffery H, Roberts MJ, McGee JP, Davis SS. Controlled release microparticles for vaccine development. Vaccine9(10), 768–771 (1991).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Rahman D, McGee JP et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology73(2), 239–242. (1991).
   PubMed Web of Science ®Google Scholar
• Johnson OL, Cleland JL, Lee HJ et al. A month-long effect from a single injection of microencapsulated human growth hormone. Nat. Med.2(7), 795–799 (1996).
   PubMed Web of Science ®Google Scholar
• Singh M, Ott G, Kazzaz J et al. Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA. Pharm. Res.18(10), 1476–1479 (2001).
   PubMed Web of Science ®Google Scholar
• Singh M, Chesko J, Kazzaz J et al. Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2SF162) to anionic PLG microparticles retains the structural integrity of the protein, while encapsulation in PLG microparticles does not. Pharm. Res.21(12), 2148–2152 (2004).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Singh M, Gupta RK. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv. Drug Deliv. Rev.32, 225–246 (1998).
   PubMed Web of Science ®Google Scholar
• Schwendeman SP, Costantino HR, Gupta RK et al. Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation. Proc. Natl Acad. Sci. USA92(24), 11234–11238 (1995).
   PubMed Web of Science ®Google Scholar
• Johansen P, Gander B, Merkle HP, Sesardic D. Ambiguities in the preclinical quality assessment of microparticulate vaccines. Trends Biotechnol.18(5), 203–211 (2000).
   PubMed Web of Science ®Google Scholar
• Sasiak AB, Bolgiano B, Crane DT et al. Comparison of in vitro and in vivo methods to study stability of PLGA microencapsulated tetanus toxoid vaccines. Vaccine19(7–8), 694–705 (2001).
   Web of Science ®Google Scholar
• Shi L, Caulfield MJ, Chern RT et al. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres. J. Pharm. Sci.91(4), 1019–1035 (2002).
   PubMed Web of Science ®Google Scholar
• Singh M, Li XM, McGee JP et al. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. Vaccine15(5), 475–481 (1997).
   PubMed Web of Science ®Google Scholar
• Pandit S, Cevher E, Zariwala MG, Somavarapu S, Alpar HO. Enhancement of immune response of HBsAg loaded poly (L-lactic acid) microspheres against hepatitis B through incorporation of alum and chitosan. J. Microencapsul.24(6), 539–552 (2007).
   PubMed Web of Science ®Google Scholar
• Men Y, Thomasin C, Merkle HP, Gander B, Corradin G. A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide. Vaccine13(7), 683–689. (1995).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Singh M, Ulmer JB. Microparticle-based technologies for vaccines. Methods40(1), 10–19 (2006).
   PubMed Web of Science ®Google Scholar
• Preis I, Langer RS. A single-step immunization by sustained antigen release. J. Immunol. Methods28(1–2), 193–197 (1979).
   PubMed Web of Science ®Google Scholar
• Gupta RK, Singh M, O’Hagan DT. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv. Drug Deliv. Rev.32(3), 225–246 (1998).
   PubMed Web of Science ®Google Scholar
• Otten GR, Schaefer M, Doe B et al. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming–boosting regimen with recombinant proteins. J. Virol.79(13), 8189–8200 (2005).
   PubMed Web of Science ®Google Scholar
• Katare YK, Panda AK, Lalwani K, Haque IU, Ali MM. Potentiation of immune response from polymer-entrapped antigen: toward development of single dose tetanus toxoid vaccine. Drug Deliv.10(4), 231–238 (2003).
   PubMed Web of Science ®Google Scholar
• Nagamoto T, Hattori Y, Takayama K, Maitani Y. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm. Res.21(4), 671–674 (2004).
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. Phagocytosis of polymer microspheres by macrophages. Adv. Polymer Sci.94, 107–141 (1990).
   Web of Science ®Google Scholar
• Thiele L, Rothen-Rutishauser B, Jilek S et al. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J. Control. Release76(1–2), 59–71 (2001).
   PubMed Web of Science ®Google Scholar
• Minigo G, Scholzen A, Tang CK et al. Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy. Vaccine25(7), 1316–1327 (2007).
   PubMed Web of Science ®Google Scholar
• Gomez S, Gamazo C, San Roman B et al. Development of a novel vaccine delivery system based on Gantrez nanoparticles. J. Nanosci. Nanotechnol.6, 3283–3289 (2006).
   PubMed Web of Science ®Google Scholar
• Arbos P, Arangoa MA, Campanero MA, Irache JM. Quantification of the bioadhesive properties of protein-coated PVM/MA nanoparticles. Int. J. Pharm.242(1–2), 129–136 (2002).
   PubMed Web of Science ®Google Scholar
• Nixon DF, Hioe C, Chen PD et al. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine14(16), 1523–1530 (1996).
   PubMed Web of Science ®Google Scholar
• Vyas SP, Gupta PN. Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev. Vaccines6(3), 401–418 (2007).
   PubMed Web of Science ®Google Scholar
• Brayden DJ, Baird AW. Microparticle vaccine approaches to stimulate mucosal immunisation. Microbes Infect.3(10), 867–876 (2001).
   PubMed Web of Science ®Google Scholar
• Florence AT. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm. Res.14(3), 259–266 (1997).
   PubMed Web of Science ®Google Scholar
• Vila A, Sanchez A, Janes K et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm.57(1), 123–131 (2004).
   PubMed Web of Science ®Google Scholar
• He Q, Mitchell A, Morcol T, Bell SJ. Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clin. Diagn. Lab. Immunol.9(5), 1021–1024 (2002).
   PubMedGoogle Scholar
• Chen H, Langer R. Oral particulate delivery: status and future trends. Adv. Drug Deliv. Rev.34, 339–350 (1998).
   PubMed Web of Science ®Google Scholar
• des Rieux A, Fievez V, Garinot M, Schneider Y-J, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release116(1), 1–27 (2006).
   PubMed Web of Science ®Google Scholar
• Garinot M, Fievez V, Pourcelle V et al. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Control. Release120(3), 195–204 (2007).
   PubMed Web of Science ®Google Scholar
• Wendorf J, Singh M, O’Hagan DT. Nanoparticles and microparticles as vaccine adjuvants. In: Nanoparticulates as Drug Carriers. Torchilin V (Ed.). Imperial College Press, London, UK, 675 (2006).
   Google Scholar
• Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med.5(4), 387–391 (1999).
   PubMed Web of Science ®Google Scholar
• Bivas-Benita M, van Meijgaarden KE, Franken KLMC et al. Pulmonary delivery of chitosan–DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine22(13–14), 1609–1615 (2004).
   PubMed Web of Science ®Google Scholar
• Locher CP, Putnam D, Langer R et al. Enhancement of a human immunodeficiency virus env DNA vaccine using a novel polycationic nanoparticle formulation. Immunol. Lett.90(2–3), 67–70 (2003).
   PubMed Web of Science ®Google Scholar
• Briones M, Singh M, Ugozzoli M et al. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. Pharm. Res.18(5), 709–712 (2001).
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres. J. Pharm. Pharmacol.39(9), 698–704. (1987).
   PubMed Web of Science ®Google Scholar
• Puri N, Sinko PJ. Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. II. In vivo investigation. J. Control. Release69(1), 69–80. (2000).
   PubMed Web of Science ®Google Scholar
• Tabata Y, Ikada Y. Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers. J. Biomed. Mater. Res.22(10), 837–858. (1988).
   PubMed Web of Science ®Google Scholar
• Sparwasser T, Hultner L, Koch ES et al. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J. Immunol.162(4), 2368–2374 (1999).
   PubMed Web of Science ®Google Scholar
• Lipford GB, Sparwasser T, Zimmermann S, Heeg K, Wagner H. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J. Immunol.165(3), 1228–1235 (2000).
   PubMed Web of Science ®Google Scholar
• Segal BM, Chang JT, Shevach EM. CpG Oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J. Immunol.164(11), 5683–5688 (2000).
   PubMed Web of Science ®Google Scholar
• Diwan M, Elamanchili P, Lane H, Gainer A, Samuel J. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. J. Drug Target.11(8), 495–507 (2003).
   PubMed Web of Science ®Google Scholar
• Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly(L,-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Presented at: The 1st International Modern Vaccine Adjuvants and Delivery Systems Meeting. Dublin, Ireland, 4–6 June 2003. 22(19), 2406–2412 (2004).
   Google Scholar
• Diwan M, Elamanchili P, Cao M, Samuel J. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. Curr. Drug Deliv.1, 405–412 (2004).
   PubMedGoogle Scholar
• Masson V, Maurin F, Fessi H, Devissaguet JP. Influence of sterilization processes on poly(ε-caprolactone) nanospheres. Biomaterials18(4), 327–335 (1997).
   PubMed Web of Science ®Google Scholar
• Konan YN, Gurny R, Allemann E. Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int. J. Pharm.233(1–2), 239–252 (2002).
   PubMed Web of Science ®Google Scholar
• Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Further application of a modified spontaneous emulsification solvent diffusion method to various types of PLGA and PLA polymers for preparation of nanoparticles. Powder Technol.107(1–2), 137–143 (2000).
   Web of Science ®Google Scholar
• Bisht S, Bhakta G, Mitra S, Maitra A. pDNA loaded calcium phosphate nanoparticles: highly efficient non-viral vector for gene delivery. Int. J. Pharm.288(1), 157–168 (2005).
   PubMed Web of Science ®Google Scholar
• Debin A, Kravtzoff R, Santiago JV et al. Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine20(21–22), 2752–2763 (2002).
   PubMed Web of Science ®Google Scholar